<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101318</url>
  </required_header>
  <id_info>
    <org_study_id>CP288</org_study_id>
    <nct_id>NCT04101318</nct_id>
  </id_info>
  <brief_title>Investigation of a New Stoma Product for People With a Stoma</brief_title>
  <acronym>CP288</acronym>
  <official_title>Investigation of a New Stoma Product for People With a Stoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CP288 study is an investigation of a non-CE marked stoma product which will be conducted
      in the UK, Italy, Netherlands, Germany, and Norway. The study will enroll up to 100 subjects.
      The study is a randomized, open-label, comparative study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Itching</measure>
    <time_frame>12 weeks</time_frame>
    <description>Max Itching score within a week at steady sate based on a new Skin Tool</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Peristomal Skin Complication</condition>
  <arm_group>
    <arm_group_label>New Stoma Baseplate with Protective Layer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New Stoma baseplate with Protective layer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-piece and 2-piece stoma devices already on the market.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>New Stoma Baseplat based on the Sensuro Mio product line.</intervention_name>
    <description>New Stoma Baseplate based on the Sensuro Mio product line. New Baseplate is not named at this point, but has a new protective layer.</description>
    <arm_group_label>New Stoma Baseplate with Protective Layer</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has given informed consent to participate by signing the informed consent signature
             form.

          2. Has an ileostomy or colostomy with liquid output (defined by a 6-7 on the Bristol
             Scale)

          3. Currently using a flat product

          4. Be at least 18 years of age and have full legal capacity

          5. Have had their stoma for at least three months (90 days)

          6. Can use a product with a max cut size of 40 mm

          7. Has experienced leakage* under the baseplate at least three times within the last 14
             days. *leakage defined as output seeping under the baseplate (Appendix 6 -
             Classification of leakage)

          8. Has symptoms of peristomal skin complications or has peristomal skin complications
             defined by at least one of the below

               1. Has experienced symptoms of skin complications (itching, burning, pain) within
                  the last fourteen days

               2. Has experienced red skin in the inner circle (within three cm from stoma edge)
                  within the last fourteen days

               3. Has skin complication (assessed by Principal Investigator, or delegate) in the
                  inner circle (within three cm from stoma edge) of the peristomal area

          9. Is able to handle the electronic diary (questionnaire/ photo) themselves.

         10. Is able to handle (apply, remove, cut etc.) the product themselves

         11. Is willing to not use barrier film or barrier cream during the investigation

         12. Is willing and suitable (determined by Principal Investigator, or delegate) to use a
             flat custom cut one-piece open or a two-piece open product during the investigation.

         13. Is willing to change the product (1pc) or baseplate (2pc) at least every fourth days.

        Exclusion Criteria:

          1. Is currently receiving or have within the past 60 days received radio-and/or
             chemotherapy

             - low doses chemotherapy (assessed by Principal Investigator) is allowed for
             indications other than cancer.

          2. Is currently receiving or have within the past month received topical steroid
             treatment in the peristomal skin area, e.g. lotion or spray.

               -  Low dose systemic steroid treatment (e.g. inhalation) assessed by the Principal
                  Investigator are allowed.

               -  Other systemic steroid treatment (e.g. injection, or tablet) are not allowed.

          3. Is breastfeeding

          4. Is pregnant (based on pregnancy test -urine)

          5. Has known hypersensitivity towards any of the products used in the investigation

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carri A Browne</last_name>
    <phone>+4521440361</phone>
    <email>dkcarr@coloplast.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ragene Saetre</name>
      <address>
        <city>Larvik</city>
        <zip>3256</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ragne Saetre, RN</last_name>
      <phone>0047 913 66 962</phone>
      <email>ragne@sykepleierklinikken.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

